studiedDrug

47 triples

GPTKB property

testedDrug

Subject	Object
gptkb:COVID-19_Solidarity_Trial_(WHO)	hydroxychloroquine
gptkb:Solidarity_trial_(WHO)	hydroxychloroquine
gptkb:Solidarity_trial_(WHO)	gptkb:interferon_beta-1a
gptkb:Rivaroxaban_Once_Daily_Oral_Direct_Factor_Xa_Inhibition_Compared_with_Vitamin_K_Antagonism_for_Prevention_of_Stroke_and_Embolism_Trial_in_Atrial_Fibrillation	gptkb:rivaroxaban
gptkb:SURPASS-3	gptkb:tirzepatide
gptkb:PolyHeme_Phase_III_Clinical_Trial	gptkb:PolyHeme
gptkb:COVID-19_Solidarity_Trial_(WHO)	gptkb:lopinavir/ritonavir
gptkb:ELIANA_trial	gptkb:tisagenlecleucel
gptkb:Solidarity_trial_(WHO)	gptkb:lopinavir/ritonavir
gptkb:JUPITER_trial	gptkb:rosuvastatin
gptkb:CheckMate_227	gptkb:ipilimumab
gptkb:SURPASS-2	gptkb:tirzepatide
gptkb:VISION_trial	177Lu-PSMA-617
gptkb:KEYNOTE-024:_Pembrolizumab_versus_Chemotherapy_for_PD-L1–Positive_Non–Small-Cell_Lung_Cancer	gptkb:pembrolizumab
gptkb:Solidarity_trial	hydroxychloroquine
gptkb:REDUCE-IT	gptkb:icosapent_ethyl
gptkb:Solidarity_trial	gptkb:interferon_beta-1a
gptkb:CheckMate_227	gptkb:nivolumab
gptkb:Adaptive_COVID-19_Treatment_Trial_1	gptkb:remdesivir
gptkb:CALM_trial	gptkb:adalimumab